1-3 of 3
Shulian Xia
Close
Sort by
Journal Articles

The Efficacy of Chidamide Maintenance Therapy after CAR-T Therapy for Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

Xian Zhang, Lefu Huang, Gailing Zhang, Yunchao Su, Xiaona Hu, Shulian Xia, Jingjing Li, Peihua Lu
Journal: Blood
Blood (2022) 140 (Supplement 1): 8884–8885.
https://doi.org/10.1182/blood-2022-168603
Published: 2022
Journal Articles

A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Jiasheng Wang, Yue Liu, Junfang Yang, Jingjing Li, Gailing Zhang, MD, Yanze Shi, Jiujiang He, Dan Song, Wenqian Li, Shulian Xia, Min Zhang, Zhixiao Zhou, Lemei Jia, Hongli Zheng, Xin Lin, Peihua Lu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-136833
Published: 2020
Journal Articles

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

Junfang Yang, MD, Jiaping He, Xian Zhang, MD, Zhenguang Wang, Yongliang Zhang, Songbai Cai, Zhe Sun, Xun Ye, Yan He, Lianjun Shen, MD PhD, Jiujiang He, Gailing Zhang, MD, Dan Song, Min Zhang, Xiaona Hu, Jingjing Li, Shulian Xia, Li Xu, Wei Cao, Peihua Lu
Journal: Blood
Blood (2019) 134 (Supplement_1): 825.
https://doi.org/10.1182/blood-2019-121751
Published: 2019